#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Arginase deficiency Turner's syndrome Primary hyperoxaluria Dementia Alzheimer's type Post transplant lymphoproliferative disorder ABO haemolytic disease of newborn Myeloproliferative neoplasm Fabry's disease Mitochondrial encephalomyopathy Hereditary optic atrophy Glomerulonephritis membranoproliferative Synovial sarcoma Narcolepsy Chronic myelomonocytic leukaemia Cardiac failure acute More trials…

    Learn about Rare Diseases

    Pemphigus – Diagnostics Acquired haemophilia – Life with Disease Lymphatic malformation – Life with Disease Brain stem glioma – Diagnostics Glycogen storage disease type V – Diagnostics Adrenocortical carcinoma Pleomorphic leiomyosarcoma – Life with Disease Osteosarcoma – Basic Information Aicardi-Goutieres syndrome – Life with Disease Gastrointestinal stromal tumour – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    AZD0120 Oxygen Pd01B Edotreotide Mesenchymal Cells POLYSORBATE 80 Trientine Dihydrochloride Betula Verrucosa Pollen Sodium Iodide (131I) VTX2735 SODIUM Tildacerfont Immunoglobulin M Omp64 Cdr132L Sodium Natalizumab Levamlodipine Succinate Amylase DNL593 Iti-1284 Timbetasin Acetate More therapies…

    Learn about Your Condition

    Multiple sclerosis Lichen planopilaris Haemoptysis Haemorrhage prophylaxis Aortic valve disease Hypercholesterolaemia Peritoneal abscess Hyperkalaemia Adenovirus infection Diabetes insipidus Corneal graft failure Traumatic pain Juvenile spondyloarthritis Testicular leiomyosarcoma Systemic infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Uveal melanoma

  • Study on Melatonin for Patients with Uveal Melanoma to Prevent Metastasis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Uveal melanoma
    Investigated Drugs:
    • Melatonin
    Sweden

  • Study of Tebentafusp and Pembrolizumab for Patients with Previously Treated Advanced Melanoma

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Tebentafusp
    • Dexamethasone Phosphate
    • Dexamethasone
    Austria Belgium France Germany Italy Poland +1

  • A Study of Darovasertib Before Surgery or Radiation Therapy for Patients with Early-Stage Uveal Melanoma That Has Not Spread

    Recruiting

    3 1 1
    Investigated Diseases:
    • Uveal melanoma
    Investigated Drugs:
    • Darovasertib
    Austria Belgium Czechia Denmark France Germany +4

  • A study comparing RP2 with nivolumab versus ipilimumab with nivolumab in adults with metastatic uveal melanoma not previously treated with immune checkpoint inhibitors

    Not yet recruiting

    4 1 1 1
    Investigated Diseases:
    • Uveal melanoma
    Investigated Drugs:
    • RP2
    • Ipilimumab
    • Nivolumab
    France Germany Italy Poland Spain

  • Study of DYP688 for Patients with Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Uveal melanoma
    • Skin cancer
    Investigated Drugs:
    • Dyp688
    France Germany The Netherlands Spain

  • Study of Darovasertib and Crizotinib for Patients with HLA-A2 Negative Metastatic Uveal Melanoma

    Not yet recruiting

    4 1 1 1
    Investigated Diseases:
    • Uveal melanoma
    Investigated Drugs:
    • Dacarbazine
    • Darovasertib
    • Crizotinib
    Belgium
Previous Page
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!